A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.